Why the study?
Liposarcoma is insensitive to traditional radiotherapy and chemotherapy and has a poor prognosis, while recent advances in molecular genetics have deepened the understanding of its pathogenic mechanisms.
Advances in understanding the molecular genetics of liposarcoma are driving the development of novel targeted therapies and immunotherapies.
Should not yet alter liposarcoma management; leaves open whether CDK4/MDM2 or NY-ESO-1 therapies will improve outcomes.
Liposarcoma is a malignant tumor of mesenchymal origin with significant tissue diversity. It is composed of adipocytes with different degrees of differentiation and different degrees of heteromorphosis. It is not sensitive to traditional radiotherapy and chemotherapy and has a poor prognosis. In recent years, with the rapid development of basic immunology, molecular genetics and tumor molecular biology, the histological classification of liposarcoma has become increasingly clear. More and more new methods and technologies, such as gene expression profile analysis, the whole genome sequencing, miRNA expression profile analysis and RNA sequencing, have been successfully applied to liposarcoma, bringing about a deeper understanding of gene expression changes and molecular pathogenic mechanisms in the occurrence and development of liposarcoma. This study reviews the present research status and progress of cellular and molecular alterations of liposarcoma and corresponding clinical treatment progress.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: